1 insider bought €29k of shares over the last 90 days, the latest by 민택근, filed 31 Aug 2026.
GemVax&KAEL Co.,Ltd.: what insiders have been doing
This page follows insider dealings at GemVax&KAEL Co.,Ltd. as filed with DART (FSS), a company from the Health Care sector. Between 26 October 2025 and 26 October 2026, 6 insiders published 29 filings.
Open-market activity splits into 9 purchases totalling €3.3M and 12 sales totalling €1.7M; 3 insiders sit on the buying side and 3 insiders on the selling side. The amount is not disclosed for 16 filings. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. On the buying side, the filings list 2 chief executives among the declarants. The largest single trade was a purchase of €3.1M by 젬앤컴퍼니, published on 24 March 2026, equal to 1.0% of the market capitalisation.
The clock since the last published purchase (31 August 2026) now reads 70 days. Typically, a trade is published a median of 7 days after it takes place. Until a filing is published, the market cannot know about the trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
With 29 filings in twelve months, the company is more active than the median of 7 filings across the 2,651 companies we follow on the same exchange. Looking back to 2021, when coverage begins, insiders filed 76 purchases and 19 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- -51.5%Entry ₩19,100 · Close 23 Oct 2026 ₩9,260
- +250.4%Entry ₩13,770 · Close at T+365 ₩48,250
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- 4,030 sharesShareKRXDART:20260831001310Canonical exit: 29 Nov 2026 (T+90)
- Other0DART
- Other0DART
- 86,500 sharesShareKRXDART:20260818000222
- Other0DART
- Other0DART
- 55,348 sharesShareKRXDART:20260619000531Canonical exit: 17 Sept 2026 (T+90)
- KRXDART:20260617000015
- ●Executives0DART
- ●Executives0DART
- 19,956 shares0.082% mcap4.4% of flowKRXDART:20260513000830Canonical exit: 4 Aug 2026 (T+90)
- 8,500 shares0.042% mcap2.5% of flowKRXDART:20260420000426
- 57,066 shares0.31% mcap18.1% of flowKRXDART:20260406003967
- 42,066 sharesShareKRXDART:20260406003941
- 150,000 shares1.04% mcap61.2% of flowKRXDART:20260324000883Canonical exit: 17 Jun 2026 (T+90)
25 of 154 declarations
About GemVax&KAEL Co.,Ltd.
Gemvax is a company operating in the health and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative treatments and therapeutic solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
